IL17A and rheumatoid arthritis: These selective immunotherapies are designed to suppress major pro-inflammatory signaling pathways by blocking inflammatory cytokines (e.g., anti-interleukin (IL)-17 in psoriasis), target immune cells (e.g., anti-B-cell activating factor (BAFF) in SLE), or intracellular kinases (e.g., Janus kinase (JAK) inhibitors in RA).